⌕
Tyra Biosciences · TYRA · Nasdaq
Tenet 65 · Solid
Compare
$19.57−0.86%At closeTenet 65 · Solid
$19.57−0.17 (−0.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Tyra Biosciences (TYRA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+42.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼38.7%
−119.9
FY21→FY25CAGR —
Free cash flow ($M)▼35.3%
−95.3
FY21→FY25CAGR —
Diluted EPS▼33.1%
−2.01
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+42.3%

41.9mn → 59.6mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.

Capex
$141.0K

−78.8% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−102.9R&D−29.8SG&A−132.8Op income12.8Tax & other−119.9Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
143,997.0102,928.080,077.062,518.043,008.020,636.0▲28.5%+49.4%
Selling, general & admin
38,405.029,834.024,100.017,427.015,919.05,652.0▲23.8%+51.6%
Total operating expenses
182,402.0132,762.0104,177.079,945.058,927.026,288.0▲27.4%+49.9%
Operating incomefeeds ROC rank
−182,402.0−132,762.0−104,177.0−79,945.0−58,927.0−26,288.0▼27.4%—
Other income, net
12,583.012,815.017,696.010,811.03,602.0−6.0——
Pretax income
−169,819.0−119,947.0−86,481.0−69,134.0−55,325.0−26,294.0▼38.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−169,819.0−119,947.0−86,481.0−69,134.0−55,325.0−26,294.0▼38.7%—
Per share
Diluted EPSbuyback-sensitive
−2.64−2.01−1.51−1.62−1.32−1.91▼33.1%—
Diluted shares (mn)
69.0859.6057.2242.7041.8813.78▲4.2%+44.2%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.